Skip to main content

Silence Therapeutics Begins Exclusive Nasdaq Trading

Written by Customer Service on . Posted in Public Companies.

Silence Therapeutics Begins Exclusive Nasdaq Trading

30 November 2021

LONDON, Silence Therapeutics plc, Nasdaq:SLN (“Silence” or “the Company“), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the cancellation of admission of its ordinary shares of nominal value £0.05 each (the “Ordinary Shares”) to trading on AIM (the “AIM Delisting”) was effective from 7:00 a.m. (London time) today.

Silence’s American Depositary Shares, each representing three Ordinary Shares (the “ADSs”), are now listed and only tradeable on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol SLN.

Mark Rothera, President and Chief Executive Officer of Silence, said: “Listing solely on the Nasdaq supports our strategy to attract high quality U.S. institutional healthcare funds as Silence gears up for the next phase of growth based on maximizing our proprietary mRNAi GOLD™ platform.”   

As previously announced, the last day of trading of the Company’s Ordinary Shares on AIM was 29 November 2021. Information about the process to deposit Ordinary Shares for delivery of ADSs was provided in the announcement and circular published by the Company on 15 October 2021 and is also available on the Company’s website at www.silence-therapeutics.com/investors/AIM-Delisting.

Enquiries:

Silence Therapeutics plc

Gem Hopkins, Head of IR & Corporate Communications

Tel:  +1 (646) 637-3208
European PR

Consilium Strategic Communications

Mary-Jane Elliott/Chris Welsh/Angela Gray

silencetherapeutics@consilium-comms.com

 

Tel: +44 (0) 20 3709 5700

About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence’s proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence’s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.